Prescription drug · ANDA
Ranolazine NDC 73141-021
Ranolazine 500 mg/1 · Tablet, Film coated, Extended release · Oral · A2A Integrated Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73141-021-02 | 73141002102 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73141-021-02)Marketed from Apr 8, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ranolazine
- Generic name (nonproprietary)
- ranolazine
- Active ingredients
- Ranolazine — 500 mg/1
- Dosage form
- Tablet, Film coated, Extended release
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213517
- Marketing start
- Listing expires
- Other FDA classes
- Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)P-Glycoprotein Inhibitors (Mechanism)
- Identifiers
- Product ID 73141-021_32becc54-372f-b7eb-e063-6294a90a48b0SPL ID 32becc54-372f-b7eb-e063-6294a90a48b0SPL set ID 9fb62878-c76a-4be2-99be-962ce2956af2RxCUI 616749, 728231UNII A6IEZ5M406UPC 0373141021020, 0373141022027
- Pharmacologic class
- Anti-anginal
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N473141002102followed by a unit qualifier and the quantityPackage 73141-0021-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Ranolazine Extended-Release Tablets are indicated for the treatment of chronic angina. Ranolazine Extended-Release Tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. Ranolazine Extended-Release Tablets is an antianginal indicated for the treatment of chronic angina. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 213517
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ranolazine | Ranolazine 1000 mg/1 | Tablet, Film coated, Extended releaseOral | A2A Integrated Pharmaceuticals | 73141-022 |
| Ranolazine | Ranolazine 500 mg/1 | Tablet, Film coated, Extended releaseOral | Bryant Ranch Prepack | 71335-2556 |
| Ranolazine | Ranolazine 500 mg/1 | Tablet, Film coated, Extended releaseOral | i3 Pharmaceuticals, LLC | 72319-021 |
| Ranolazine | Ranolazine 1000 mg/1 | Tablet, Film coated, Extended releaseOral | i3 Pharmaceuticals, LLC | 72319-022 |